Workshop on Ewing's Sarcoma
Author Information
Author(s): A.J. Malcolm, B.D. Young, S. Nasipuri, F.E. Cotter, F.C. Oliff, F.A. Hayes, E.I. Thompson, L. Kun, B. Rao, M. Kumar, W. Myer, H.O. Hustu, H. Jurgens, A.W. Craft, O. Oberlin, M. Brunat-Mentigny, F. Pein, M.C. Demaille, J.M. Zucker, P. Lutz, J.P. Vannier, P. Boutard, C. Behar, M. Jullien, P. Terrier, J. Lemerle, P.N. Plowman, R.L. Souhami, C.R. Pinkerton, J.S. Malpas
Conclusion
The studies suggest that Ewing's sarcoma has varying degrees of neural differentiation and that treatment strategies need to be refined for better outcomes.
Supporting Evidence
- About 25% of previously described Ewing's tumours have some neural differentiation and might now be called PNETs.
- The 5-year disease-free survival for patients with localized disease is 61%.
- The overall survival for patients with localized disease is 78%.
- Low doses of cyclophosphamide and adriamycin are effective induction therapies.
- Patients with small lesions have better disease control compared to those with larger lesions.
Takeaway
Ewing's sarcoma is a type of bone cancer that can look different under a microscope, and doctors are trying to find the best ways to treat it.
Methodology
The workshop included discussions on various studies related to Ewing's sarcoma, including treatment protocols and outcomes.
Limitations
The rarity of Ewing's sarcoma makes it difficult to conduct large-scale randomized trials.
Participant Demographics
Patients ranged from 2 years 10 months to 21 years 11 months, with a median age of 15 years.
Statistical Information
P-Value
0.025
Statistical Significance
p=0.025
Want to read the original?
Access the complete publication on the publisher's website